CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Gerigene Medical Corporation

Gerigene Medical Corporation is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kalypsys

Kalypsys, Inc. is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

major pharmaceuticals

major pharmaceuticals is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anji Pharmaceuticals

Anji Pharma is a global pharmaceutical company focused on tackling high-value targets validated by human genetics. We are exhaustive in our discovery and clinical efforts while nimble in our strategy and execution. We have assembled a world-class team of scientist entrepreneurs who are committed to accelerate innovative medicines in China and worldwide.

Janssen Pharmaceuticals

Janssen Pharmaceuticals is a Titusville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.